Invitrolize develops the ALIsens platform, a patented 3D alveolar in vitro model that accurately identifies and differentiates respiratory sensitizers from irritants under realistic air-liquid interphase exposure conditions. This technology addresses the need for early detection of harmful respiratory compounds, helping industries comply with upcoming regulatory requirements and mitigate risks associated with hazardous materials.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LFounders
Product
Problem
Current methods for identifying respiratory sensitizers and irritants often rely on animal testing, which raises ethical concerns and may not accurately reflect human responses. Traditional in vitro models may also lack the complexity needed to mimic the air-liquid interface of the human alveolar region, leading to inaccurate hazard assessments. The industry anticipates mandatory respiratory testing in the near future, increasing the urgency for reliable and human-relevant testing methods.
Solution
Invitrolize offers ALIsens, a patented 3D alveolar in vitro model that accurately identifies and differentiates respiratory sensitizers from irritants under realistic air-liquid interphase exposure conditions. The ALIsens model uses a complex 3D cell culture to mimic the human alveolar region, providing a more accurate and ethical alternative to animal testing. This allows for early detection of harmful respiratory compounds, helping industries comply with upcoming regulatory requirements and mitigate risks associated with hazardous materials. The model is suitable for toxicological testing and has demonstrated high specificity, with ongoing efforts to achieve OECD guideline validation.
Target Audience
The primary target audience includes pharmaceutical, cosmetics, chemical, food, environment, consumer product, manufacturing, crop protection, and tobacco industries seeking reliable and ethical respiratory toxicity testing.
Features
- Patented 3D alveolar in vitro model that mimics the air-liquid interface of the human lung
- Capable of identifying and differentiating respiratory sensitizers and irritants
- High specificity (>95%) in identifying respiratory hazards
- Valid for toxicological testing of inhalable drugs, cosmetics, chemicals, food-born proteins, environmental particles, consumer products, and tobacco ingredients
- Suitable for hazard assessment early in product development
- Designed for use with exposure systems suitable for all types of airborne materials
- Currently undergoing pre-validation for OECD test guideline submission
- Compatible with Good In Vitro Method Practices (GIVIMP)
- Can be run in parallel with primary cell-based models for comprehensive testing batteries
- Implementation of ELN+LIMS platform for streamlined workflows and data integrity